ER & PR receptor assays are routinely performed on Breast carcinomas to assess responsiveness to endocrine therapy and prognosis. CA 15.3 is useful for monitoring response to treatment and if elevated suggests recurrence in women with Stage II or III breast cancer.

  • Test Type:
  • Pre-test Information:
    Give brief clinical history
  • Report Delivery:
    Sample Daily by 6 pm Report 5 days: Blocks / Sections / Smears 7 days: Tissue Same Day : CA 15.3
  • Components:

Sample Report

metastatic breast cancer markers in other Cities